Citations

Clear

3942 citation(s) found for "To, Van".

Abstract 16803: Relationships Between Invasive and Non-invasive Measures of Cardiac Function During Exercise in Heart Failure With Preserved or Reduced Ejection Fraction
Snyder, Eric M, Borlaug, Barry A, Olson, Thomas P. , Iterson, Erik H. Van , Snyder, Eric M., Borlaug, Barry A.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.16803 Get It

Introduction: Assessment of cardiac function during exercise is critical in the clinical evaluation of patients with heart failure with preserved (HFpEF) or reduced (HFrEF) ejection fraction. Direct invasive measurement of cardiac power (CP) and stroke work (SW) are robust measures of cardiac function. Non-invasive gas exchange based surrogates may provide practical means of assessing cardiac function in clinical and research settings; however, the relationship between invasive and non-invasive measurement of CP or SW during exercise is unclear in HFpEF and HFrEF. We aimed to assess relationships between invasive and non-invasive measures of CP and SW during exercise in HFpEF and HFrEF. Methods: HFpEF (n=47) and HFrEF (n=29) (age 71±10 vs 55±10 yrs; EF% 62±8 vs 21±6%; BSA 2.1±0.3 vs 2.1±0.2 m 2 ; weight 99±22 vs 87±15 kg; peak work 36±14 vs 37±13 watts (W), respectively; all p<0.05, except peak work) underwent peak exercise testing during right heart catheterization. Invasive measurement of cardiac pressures, hemodynamics, and arterial pressures were recorded at rest, 20 W, and peak work. Continuous measurement of HR and VO 2 occurred from rest to peak work via 12-lead ECG and metabolic measurement system, respectively. Invasive measurements were calculated as, CP=(MAP–RAP) x Q x 2.22х10 -3 ; SW=(MAP–PCWP) x SV I x 0.133; and non-invasive as, CP=VO 2 x MAP; SW=VO 2 /HR x MAP. All indices adjusted for body surface area. Results: At rest, there were moderate relationships between invasive and non-invasive measures of CP and SW in HFpEF (r=0.56 and 0.48) and HFrEF (0.57 and 0.73), respectively (all p<0.05). At 20 W, relationships between invasive and non-invasive measures of CP and SW strengthened in HFpEF (r=0.74 and 0.69) and HFrEF (0.74 and 0.72), respectively (all p<0.05). The relationships noted between invasive and non-invasive measures of CP and SW at 20 W persisted at peak work in HFpEF (r=0.74 and 0.67) and HFrEF (0.78 and 0.69), respectively (all p<0.05). Conclusion: These data suggest that non-invasive estimates of CP and SW correlate closely with invasive measures and may be reasonable surrogates for these indices during peak exercise testing in both HFpEF and HFrEF patients.
Abstract 16798: The Influence of Heart Failure With Preserved or Reduced Ejection Fraction on Relationships Between Cardiac Power and Stroke Work With VO2
Snyder, Eric M., Olson, Thomas P. , Iterson, Erik H. Van , Borlaug, Barry A.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.16798 Get It

Introduction: Invasive measurement of cardiac power (CP) and stroke work (SW) during exercise are robust indices of cardiac function and relate to syndrome severity and prognosis in heart failure patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction. Because invasive measurement via catheterization laboratories are not always readily available, non-invasive cardiopulmonary exercise testing to estimate cardiac function is routinely performed in the clinical evaluation of HFpEF and HFrEF. However, it is unknown how VO 2 relates with CP and SW in HFpEF vs HFrEF. We compared relationships between CP and SW with VO 2 at rest and peak exercise in HFpEF vs HFrEF. Methods: 30 HFpEF and 32 HFrEF (EF: 62±2 vs 22±1%; males: 17 vs 30; age: 70±2 vs 55±2 yrs; BMI: 34±1 vs 28±1 kg/m 2 ; wt: 98±4 vs 86±3 kg (all p<0.05)) participated in exercise testing during right heart catheterization. Oxygen consumption (VO 2 ) was measured continuously from rest to peak work. Invasive measures at rest and peak work included mean radial arterial pressure (MAP), right atrial pressure (RAP), and pulmonary capillary wedge pressure (PCWP). We calculated CP=(MAP–RAP) x Q I x 2.22х10 -3 and SW=(MAP–PCWP) x SV I x 0.133. Results: At rest, R 2 between VO 2 and CP or SW were not different between HFpEF (CP=0.41, SW=0.30) and HFrEF (CP=0.39, SW=0.15). Slopes did not differ significantly between HFpEF (CP=0.13, SW=0.01) and HFrEF (CP=0.16, SW=0.01) for regressions between VO 2 and CP or SW; but, fitted intercepts of the regression showed significantly higher intercepts in HFrEF (CP=0.89, SW=1.16) vs HFpEF (CP=0.05, SW=0.27) for VO 2 vs CP and SW, respectively. At peak exercise, R 2 between VO 2 and CP or SW were not different between HFpEF (CP=0.48, SW=0.64) and HFrEF (CP=0.70, SW=0.67). Slopes did not differ between HFpEF (CP=0.18, SW=0.02) and HFrEF (CP=0.15, SW=0.02) for regressions between VO 2 and CP or SW, whereas the fitted intercepts the slope of the regression were significantly higher in HFrEF (CP=5.1, SW=4.4) vs HFpEF (CP=3.2, SW=2.0) for VO 2 vs CP and SW, respectively. Conclusion: Our data suggest that despite lower VO 2 relative to CP and SW in HFpEF, both the strength of relationship and rate of increase in VO 2 relative to CP and SW are similar between HFpEF and HFrEF at rest and peak exercise.
Abstract 186: Effect of Direct Thrombin Inhibition on Vascular Function and Aortic Valve Function in Hypercholesterolemic Mice
Mehra, K. N. , Hagler, Michael A , Oehler, Elise A., Ryn, Joanne van, Mehra, Kashish, Zhang, Bin, Miller, Jordan D.

Mayo Clinic

Arteriosclerosis, Thrombosis, and Vascular Biology | March 19, 2022 | Volume: 32 | Issue: suppl_1 | Pages: No page available

10.1161/atvb.32.suppl_1.a186 Get It

Thrombin plays a major role in coagulation cascade and participates in regulation of vascular function through its effects on protease-activated receptors (PARs). The effect of thrombin inhibition on vascular and aortic valve function during prolonged hypercholesterolemia, however, remains unknown. In the present study, we tested the hypothesis that direct thrombin inhibition (DTI, dabigatran etexilate) slows progression of endothelial and aortic valve dysfunction in ldlr-deficient, apolipoprotein B100-only (LA) mice. Carotid arteries from LA mice were used for studies of endothelial function in isolated organ baths, and aortic valve function was evaluated using echocardiography. In placebo-treated mice, maximum relaxation to acetylcholine was reduced following 6 and 9 months of hypercholesterolemia (maximum relaxation to acetylcholine (MR ACH ) =75%± 3.7, and 67%± 3.6, respectively), but not affected by DTI (75%± 2.5, and 62%± 3.2, respectively). Relaxation to exogenous NO donors was also unaffected by DTI. Aortic valve function progressively deteriorated at 3, 6, and 9 months in placebo-treated mice (2.1 m/s± 0.04, 2.5 m/s± 0.1, and 2.9m/s ± 0.1, respectively), and was not affected by DTI (2.0m/s± 0.1, 2.5m/s± 0.1 and 3.0m/s ± 0.4, respectively). While PAR receptor expression was detected in aorta and aortic valve tissue, expression of SPHK1 (an indicator of PAR1 activity) was not altered by DTI. Expression of CTGF in aortic valves, however, tended to be reduced by DTI. In conclusion, our data suggest that DTI does not prevent vasomotor or aortic valve dysfunction in mice with prolonged hypercholesterolemia, but may attenuate pro-fibrotic signaling in aortic valves.
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON T
Tesileanu, C. Mircea S. , Wick, Wolfgang , Clément, Paul M. , Erridge, Sara , Vogelbaum, Michael A. , Nowak, Anna K. , Baurain, Jean‐François , Mason, Warren , Wheeler, Helen , Gill, Sanjeev , Griffin, Matthew, Rogers, Leland , Taal, Walter , Weller, Michael , McBain, Catherine , Linde, Myra E. van , Aldape, Kenneth , Jenkins, Robert B., Hoogstrate, Youri , Heer, Iris de , Atmodimedjo, Peggy N., Dubbink, Hendrikus J. , IJcken, Wilfred F. J. van , Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G. , Gorlia, Thierry, French, Pim J. , Bent, Martin J. van den , Sanson, Marc , Wick, Wolfgang , Clement, Paul M , Nowak, Anna K , Baurain, Jean-Francois , Wheeler, Helen , Chinot, Olivier L , Taal, Walter , Weller, Michael , Aldape, Kenneth , Kros, Johan M. , Wesseling, Pieter , von Deimling, Andreas , Hoogstrate, Youri , Dubbink, Hendrikus J , van IJcken, Wilfred F J , Golfinopoulos, Vassilis , French, Pim J , van den Bent, Martin J , Sanson, Marc , Brandes, Alba Ariela , Chinot, Olivier , Rudà, Roberta , Wesseling, Pieter , Deimling, Andreas von , Brouwer, Rutger W. W.

Mayo Clinic

Clinical Cancer Research | March 11, 2022 | Volume: 28 | Issue: 12 | Pages: 2527-2535

10.1158/1078-0432.ccr-21-4283 | PMID 35275197 Get It

Abstract Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase–wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and Methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82–1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61–1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.
Ultrasound Guided Biopsy in Patients With HPV‐Associated Oropharyngeal Squamous Cell Carcinoma
Haller, Travis J. , Abel, Kathryn M. Van , Lohse, Christine M. , Douse, Dontre’ M. , Badaoui, Joseph N. , Kasperbauer, Jan L. , Moore, Eric J. , Van Abel, Kathryn M , Yin, Linda X , Douse, Dontre', Kasperbauer, Jan , Moore, Eric J , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

The Laryngoscope | March 11, 2022 | Volume: 132 | Issue: 12 | Pages: 2396-2402

10.1002/lary.30105 | PMID 35275423 Get It

Objectives To identify the differences in sensitivity and accuracy between ultrasound‐guided and palpation‐guided fine needle aspirations (FNA) of suspicious lymph nodes in patients with human papillomavirus (HPV) (+) oropharyngeal squamous cell carcinoma (OPSCC). Additional objectives included identifying patient specific factors affecting biopsy accuracy and evaluating potential differences in accuracy between fine and core needle biopsies. Study Design Retrospective chart review. Materials and Methods A retrospective study of diagnostic sensitivity was completed at a single tertiary care center between 1/1/2006–12/31/2016. Participants included patients who underwent pretreatment FNA biopsy with HPV(+)OPSCC confirmed pathologically following neck dissection or excisional lymph node biopsy. A true positive (TP) on FNA biopsy was defined as an FNA biopsy concerning for squamous cell carcinoma (SCC) that was confirmed on excisional biopsy or neck dissection. A false negative (FN) was defined as a negative FNA but metastatic disease identified on excisional biopsy or neck dissection. Sensitivity was calculated as TPs/(TPs + FNs). Sensitivity was compared among techniques using chi‐square and Fisher exact tests. Results A total of 209 FNA biopsies among 198 patients were included in the study, including 31 (15%) palpation‐guided FNAs, 160 (77%) ultrasound‐guided FNAs, and 18 (9%) ultrasound‐guided FNA + core biopsies. Sensitivity was significantly different among palpation‐guided FNA, ultrasound‐guided FNA, and ultrasound‐guided FNA + core biopsies (48% vs. 83% vs. 94%, respectively; P < .001) but there was no significant difference in sensitivity between ultrasound‐guided FNA versus ultrasound‐guided FNA + core biopsies ( P = .31). Conclusion The use of ultrasound guidance in FNA biopsies of nodal metastases in HPV(+)OPSCC improves sensitivity compared to palpation guidance alone. Ultrasound guided biopsies are preferred in patients with suspected nodal metastasis from HPV(+)OPSCC. Level of Evidence 3 Laryngoscope , 132:2396–2402, 2022
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
Goyal, Gaurav , Tazi, Abdellatif , Picarsic, Jennifer , Vassallo, Robert , Cox, Christian W. , Laar, Jan van , Hermiston, Michelle L. , Haroche, Julien , Girschikofsky, Michael , Picarsic, Jennifer L , Cox, Christian W , van Laar, Jan A M , Cao, Xin-Xin , Makras, Polyzois , Kaltsas, Gregory , McClain, Kenneth L , Diamond, Eli L , Goyal, Guarav , Vassallo, Robert , Go, Ronald S. , Rech, Karen L. , Young, Jason R. , Makras, Polyzois , Kaltsas, Gregory , Collin, Matthew , McClain, Kenneth L. , Diamond, Eli L.

Mayo Clinic

Blood | March 10, 2022 | Volume: 139 | Issue: 17 | Pages: 2601-2621

10.1182/blood.2021014343 | PMID 35271698 Get It

Abstract Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management of LCH in adults are mostly derived from the pediatric literature. Over the last decade, the discovery of clonality and MAPK-ERK pathway mutations in most cases led to the recognition of LCH as a hematopoietic neoplasm, opening the doors for treatment with targeted therapies. These advances have necessitated an update of the existing recommendations for the diagnosis and treatment of LCH in adults. This document presents consensus recommendations that resulted from the discussions at the annual Histiocyte Society meeting in 2019, encompassing clinical features, classification, diagnostic criteria, treatment algorithm, and response assessment for adults with LCH. The recommendations favor the use of 18F-Fluorodeoxyglucose positron emission tomography-based imaging for staging and response assessment in the majority of cases. Most adults with unifocal disease may be cured by local therapies, while the first-line treatment for single-system pulmonary LCH remains smoking cessation. Among patients not amenable or unresponsive to these treatments and/or have multifocal and multisystem disease, systemic treatments are recommended. Preferred systemic treatments in adults with LCH include cladribine or cytarabine, with the emerging role of targeted (BRAF and MEK inhibitor) therapies. Despite documented responses to treatments, many patients struggle with a high symptom burden from pain, fatigue, and mood disorders that should be acknowledged and managed appropriately.
Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and Colorectal Cancer Risk
Shu, Xiao-Ou , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Cai, Qiuyin , Casey, Graham, Gruber, Stephen B. , Huyghe, Jeroen R. , Jee, Sun Ha, Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Ose, Jennifer , Pai, Rish K. , Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Woods, Michael O. , Wu, Anna H., Peters, Ulrike , Jee, Sun Ha , Chen, Zhishan , Shu, Xiao-Ou , Kim, Jeongseon , Kweon, Sun-Seog , Matsuda, Koichi , Matsuo, Keitaro , Ose, Jennifer , Oze, Isao , Pai, R K , Pharoah, Paul D P , Playdon, Mary C , Schoen, Robert E , Shin, Min‐Ho , Shu, Xiao-Ou , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Woods, Michael O , Peters, Ulrike , Zheng, Wei , Gruber, Stephen B , Cai, Qiuyin , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Casey, Graham, Huyghe, Jeroen R , Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Wu, Anna H.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 10, 2022 | Volume: 31 | Issue: 6 | Pages: 1216-1226

10.1158/1055-9965.epi-21-1008 | PMID 35266989 Get It

Abstract Background: The etiology of colorectal cancer is not fully understood. Methods: Using genetic variants and metabolomics data including 217 metabolites from the Framingham Heart Study (n = 1,357), we built genetic prediction models for circulating metabolites. Models with prediction R2 &gt; 0.01 (Nmetabolite = 58) were applied to predict levels of metabolites in two large consortia with a combined sample size of approximately 46,300 cases and 59,200 controls of European and approximately 21,700 cases and 47,400 controls of East Asian (EA) descent. Genetically predicted levels of metabolites were evaluated for their associations with colorectal cancer risk in logistic regressions within each racial group, after which the results were combined by meta-analysis. Results: Of the 58 metabolites tested, 24 metabolites were significantly associated with colorectal cancer risk [Benjamini–Hochberg FDR (BH-FDR) &lt; 0.05] in the European population (ORs ranged from 0.91 to 1.06; P values ranged from 0.02 to 6.4 × 10−8). Twenty one of the 24 associations were replicated in the EA population (ORs ranged from 0.26 to 1.69, BH-FDR &lt; 0.05). In addition, the genetically predicted levels of C16:0 cholesteryl ester was significantly associated with colorectal cancer risk in the EA population only (OREA: 1.94, 95% CI, 1.60−2.36, P = 2.6 × 10−11; OREUR: 1.01, 95% CI, 0.99−1.04, P = 0.3). Nineteen of the 25 metabolites were glycerophospholipids and triacylglycerols (TAG). Eighteen associations exhibited significant heterogeneity between the two racial groups (PEUR-EA-Het &lt; 0.005), which were more strongly associated in the EA population. This integrative study suggested a potential role of lipids, especially certain glycerophospholipids and TAGs, in the etiology of colorectal cancer. Conclusions: This study identified potential novel risk biomarkers for colorectal cancer by integrating genetics and circulating metabolomics data. Impact: The identified metabolites could be developed into new tools for risk assessment of colorectal cancer in both European and EA populations.
The Extracellular ATP Receptor P2RX7 Imprints a Promemory Transcriptional Signature in Effector CD8+ T Cells
Vardam-Kaur, Trupti , Dijk, Sarah van , Peng, Changwei , Wanhainen, Kelsey M. , Jameson, Stephen C. , Silva, Henrique Borges da , van Dijk, Sarah , Borges da Silva, Henrique , Jameson, Stephen C

Mayo Clinic

The Journal of Immunology | March 9, 2022 | Volume: 208 | Issue: 7 | Pages: 1686-1699

10.4049/jimmunol.2100555 | PMID 35264459 Get It

Abstract Development of CD8+ central memory T (Tcm) and resident memory T (Trm) cells, which promote immunity in the circulation and in barrier tissues, respectively, is not completely understood. Tcm and Trm cells may arise from common precursors; however, their fate-inducing signals are elusive. We found that virus-specific effector CD8+ T cells display heterogeneous expression of the extracellular ATP sensor P2RX7. P2RX7-high expression is confined, at peak effector phase, to CD62L+ memory precursors, which preferentially form Tcm cells. Among early effector CD8+ T cells, asymmetrical P2RX7 distribution correlated with distinct transcriptional signatures, with P2RX7-high cells enriched for memory and tissue residency sets. P2RX7-high early effectors preferentially form both Tcm and Trm cells. Defective Tcm and Trm cell formation in P2RX7 deficiency is significantly reverted when the transcriptional repressor Zeb2 is ablated. Mechanistically, P2RX7 negatively regulates Zeb2 expression, at least partially through TGF-β sensing in early effector CD8+ T cells. Our study indicates that unequal P2RX7 upregulation in effector CD8+ T cells is a foundational element of the early Tcm/Trm fate.
Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Potter, David A. , Roesch, Erin , Lu, Ruixiao , Samson, Susan, Stafford, Debra, Albain, Kathy S. , Chien, A. Jo , Perlmutter, Jane , Melisko, Michelle , Veer, Laura van ‘t , Wilson, Amy , Asare, Smita , Berry, Donald A. , Schwab, Richard B. , Potter, David A , Yau, Christina , Wolf, Denise M. , Isaacs, Claudine , Trivedi, Meghana V. , Yee, Douglas , Boughey, Judy C. , Thomas, Alexandra , Hylton, Nola M. , Li, Wen , DeMichele, Angela , Symmans, W. Fraser , Hershman, Dawn L. , Veer, Laura J. van’t , Rugo, Hope S. , Esserman, Laura J.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: PD8-07-PD8-07

10.1158/1538-7445.sabcs21-pd8-07 Get It

Abstract Background: I-SPY 2 is a multicenter, phase 2 trial using response-adaptive randomization within molecular subtypes defined by receptor status and MammaPrint (MP) risk to evaluate novel agents as neoadjuvant therapy for women with high-risk breast cancer. Tucatinib is a potent HER2 (ErbB2) tyrosine kinase inhibitor, selective for HER2 vs. epidermal growth factor receptor (EGFR) and is active vs. brain metastases. Safety and efficacy of tucatinib combined with paclitaxel, pertuzumab, and trastuzumab are unknown and were tested in a planned 10 patient (pt) safety run-in of the I-SPY 2 trial. Methods: Women with tumors ≥ 2.5cm were eligible for screening. Only pts with tumors that were HER2+ by FISH were eligible for this treatment. Treatment included tucatinib (max dose 300 mg) BID for 12 weeks with weekly paclitaxel 80 mg/m2 and trastuzumab (2 mg/kg weekly following loading), and pertuzumab (420 mg every 3 weeks following loading), followed by doxorubicin/cyclophosphamide (AC) every 2 weeks x 4. The control arm was weekly paclitaxel and trastuzumab with pertuzumab for 12 weeks followed by AC every 2 weeks x 4. All pts undergo serial MR imaging and response at 3 & 12 weeks is combined with real time pCR data to estimate, and continuously update, the predicted pCR rate for each trial arm. The goal of the trial is to identify/graduate regimens with ≥85.% Bayesian predictive probability of success (i.e. demonstrating superiority to control) in a future 300-patient phase 3 neoadjuvant trial with a pCR endpoint. This run-in arm was conducted to determine safety of combining tucatinib with paclitaxel/trastuzumab/pertuzumab, monitoring special adverse events of interest including LFT elevations and gastrointestinal toxicities.Methods: The I-SPY 2 methods have been previously published. Results: 20 pts were evaluable in tucatinib treatment arm. The control arm included 329 historical controls enrolled since April 2010. The initial tucatinib dose was 300 mg BID. After enrollment of the first 8 pts, there were 3 pts with grade 3 LFT elevations, 2 pts with grade 2/3 diarrhea, 1 pt with grade 2 neutropenia, and 1 pt with grade 3 nausea. After this safety review, the tucatinib dose was lowered to 250 mg BID. Among 5 additional pts enrolled, 3 developed grade 2/3 LFT abnormalities. The protocol was then modified to tucatinib 150 mg BID days 1-28 and then 250 mg BID days 29-84; 7 pts were treated. Safety data were reviewed after 20 pts were enrolled; the arm was then suspended due to similar LFT elevations regardless of tucatinib dose reduction or schedule. 7 of 20 pts (35%) had reversible Grade 3 or higher ALT/AST elevation (Table). No pt met criteria for Hy’s Law. In terms of efficacy, 12 of 14 evaluable pts had &gt; 80% reduction of tumor volume by 12 weeks, measured by MRI assessment of functional tumor volume (FTV). Conclusion: The goal of the run-in arm was to determine the safety of adding tucatinib to the combination of paclitaxel/trastuzumab/pertuzumab. The addition of tucatinib resulted in unacceptable but reversible LFT elevations despite tucatinib dose reduction. Tucatinib containing therapy resulted in &gt;80% decline in tumor volume at 12 weeks in 86% of pts. Tucatinib showed a high level of activity when combined with paclitaxel/trastuzumab/pertuzumab, but the combination is not feasible. Table: Number of pts with grade 2, 3, and 4 LFT elevations by treatment schedule (highest grade per patient per event, ALT or Treatment scheduleGrade 2 LFT elevationGrade 3 LFT elevationGrade 4 LFT elevationTucatinib 300 mg BID030Tucatinib 250 mg BID210Tucatinib 150 mg BID days 1-28 followed by 250 mg BID days 29 to 84112 Citation Format: David A Potter, Erin Roesch, Christina Yau, Ruixiao Lu, Denise Wolf, Susan Samson, Debra Stafford, Kathy S Albain, Claudine Isaacs, Meghana Trivedi, Douglas Yee, Judy Boughey, Alexandra Thomas, A. Jo Chien, Nola Hylton, Wen Li, Angela DeMichele, Jane Perlmutter, W. Fraser Symmans, Dawn L Hershman, Michelle Melisko, Laura J van 't Veer, Amy Wilson, Smita M Asare, Donald A Berry, Richard Schwab, Hope S Rugo, Laura J Esserman. Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD8-07.
Abstract P2-13-45: Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors
Tine, Brian Andrew Van, Mita, Monica , Valdes, Frances, Ahn, Daniel H. , Starr, Jason S. , Georgy, Angela, Pelham, Joshua, Anand, Banmeet S. , Strack, Thomas , Sandri, Andrés Machado, Barve, Minal , Hamilton, Erika , Brenner, Andrew Jacob , Hubbard, Joleen M. , Wainberg, Zev A.

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: P2-13-45-P2-13-45

10.1158/1538-7445.sabcs21-p2-13-45 Get It

Abstract Background: Engineered toxin bodies (ETBs) are composed of a de-immunized Shiga-like Toxin A subunit genetically fused to an antibody-like binding domain. ETBs can force receptor internalization, induce potent cell-kill via enzymatic and permanent inactivation of ribosomes, and may not be subject to resistance mechanisms of other therapeutics. MT-5111 is a 55 kD ETB targeting HER2 in solid tumors that binds to an epitope distinct from trastuzumab and pertuzumab, offering potential combination strategies with other HER2-targeting agents. MT-5111 may demonstrate efficacy in patients (pts) resistant to other HER2-targeting agents, as its mechanism of action does not rely on inhibition of kinase signaling or cytoskeletal or DNA damage. Methods: The primary objective is to determine the maximum tolerated dose (MTD) of MT-5111 monotherapy in adult pts with advanced HER2+ solid tumors. Secondary objectives are pharmacokinetics (PK), efficacy, and immunogenicity. Using a modified 3+3 design, the dose-escalation part of the study enrolls pts with HER2+ tumors into 7 cohorts: 0.5, 1, 2, 3, 4.5, 6.75, and 10 µg/kg/dose. Three dose-expansion cohorts will follow for HER2+ breast cancer, gastro-esophageal cancer, and other HER2+ tumors. All pts receive MT-5111 weekly as 30-min IV infusions in each 21-day treatment (tx) cycle (C) until disease progression (PD), unacceptable toxicity, death, or withdrawn consent (NCT04029922). Results: Per data cut in June 2021, 21 pts (mean age 64 years, range 34-78; 38% male) in cohorts 1-6 with breast (n=7), biliary (n=6), gastric (n=3), pancreatic (n=2), lung (n=2), and colon (n=1) cancer were treated (Table 1). Pts had a median of 4 prior lines of systemic therapies (range, 1-8) and 2 prior lines of HER2-targeting treatments (range, 0-6). No Grade (G)4 or 5 tx-emergent (TE) adverse events (AEs) occurred. Tx-related AEs occurred in 11 (52%) pts; the most common was fatigue (n=7, 33%). One pt (4.5 µg/kg) had a possibly (per PI) related G3 serious AE (SAE) of dyspnea and hypoxia, but also lymphangitic carcinomatosis and H. influenzae infection. The other related SAE occurred in a pt (6.75 µg/kg) who had a G1 transient troponin increase without concomitant cardiac symptoms or ECG/ECHO changes. All other related AEs were ≤G2. There were no clinically significant changes in cardiac biomarkers (troponin, ECG, left ventricular ejection fraction) nor were there cases of capillary leak syndrome. Two pts (3 µg/kg and 4.5 µg/kg) had reversible G2 infusion-related reactions. Best response to date has been stable disease. AUClast data matched PK simulations based on non-human primate studies, and Cmax data at 6.75 µg/kg indicated that current in-human exposure was between the IC50 values of high and medium HER2-expressing cell lines (approximately 10-89 ng/mL). Thus, a dose of at least 10 µg/kg may be required to achieve effective exposure. To date, no dose-limiting toxicities have been observed and the 10 µg/kg/dose cohort is now accruing. Conclusions: MT-5111 was well tolerated with no clinically significant immuno- or cardiotoxicity. Dose escalation is ongoing and nearing levels expected to be required for efficacious exposure. Table 1.Metastatic HER2 status and MT-5111 treatment by cohortDose0.5 µg/kg1.0 µg/kg2.0 µg/kg3.0 µg/kg4.5 µg/kg6.75 µg/kgCohort123456Number of patients treated with MT-5111433335Metastatic HER2 2+ by IHC: ALL/BC1/11/11/01/10/04/0Metastatic HER2 3+ by IHC: ALL/BC3/12/02/12/13/01/1BC, breast cancer. Citation Format: Brian A. Van Tine, Monica Mita, Minal A. Barve, Erika P. Hamilton, Andrew J. Brenner, Frances Valdes, Daniel Ahn, Joleen Hubbard, Jason Starr, Angela Georgy, Joshua Pelham, Banmeet S. Anand, Thomas Strack, Andrés Machado Sandri, Zev A. Wainberg. Interim results of a phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+tumors [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-13-45.